Research highlights the increased risk of ocular problems and vision loss among HZO patients with this condition, emphasizing the importance of timely antiviral treatment and follow-up care.
The noninfectious form was helped by periocular and intraocular corticosteroids. Newer delivery methods have less evidence supporting their use due to the recency of their introduction.
Though rates are low epidemiologically at 1.5 cases per one million people, the condition disproportionately affects men, African American individuals and those in the lowest income category.